After only 2 and a half months of the new Alle Rewards Program, Alle is preparing to go back to the old program as soon as February 2025. Third party sources have shared that reps are connecting with stores to share the big news, reporting less than desirable financial performance, confusion from patients, and dissatisfaction from practices regarding the shift in the program.

In working closely with practice owners, practices have described difficulties communicating the changes to patients and have been frustrated with the burden of the task, the financial impacts to their practices posed by the rewards structure, and experiencing continuous increases in supply costs all the while.

While short lived, it’s exciting to see this transition back to the original program as it posed several financial and operational challenges for practices. In addition to obstacles getting patients on board with the revamped Alle program, practices were faced with navigating how to handle patients eligible for free products. For certain earning tiers, patients would have been able to redeem points for free Botox or Juvederm. This came at the cost of the practice scheduling the patient and incurring the costs and time for administering a free treatment despite advice to charge an “injection fee”. As we can all agree, this did not sit well with the practice who had to communicate it or the patient who assumed they were going to receive a free treatment.

Third party sources have also shared that Allergan reps are passing on details around providing practices with $50 vouchers for select patients and are also planning to launch a $100 promotional new year offer for new clients and patients through the program. We’re also told that Allergan has announced that there will be either no or minimal price increases in 2025.Knowing that rising costs have been haunting practice profitability and forcing subsequent price increases passed on to patients, we’re eager to see Allergan shift their focus back to the practices by making these changes – which we’re predicting will prove for greater returns for Allergan.

Stay tuned as more concrete details should be announced to communicate these exciting new updates!